Skip to main content
. 2022 May;17(5):634–642. doi: 10.2215/CJN.12410921

Table 2.

Unadjusted study outcomes according to the continuous KRT solution group

Study Outcomes Phosphate-Free Continuous KRT Solution, n=343 Phosphate-Containing Continuous KRT Solution, n=649 P Value
Primary outcome
 Ventilator-free days at 28 d, median (IQR) 21 (16–25) 22 (17–25) 0.20a
Secondary outcomes
 Total hospital LOS, d, median (IQR) 16 (5–25) 12 (5–22) 0.01a
 Total ICU LOS, d, median (IQR) 10 (3–23) 8 (3–15) 0.01a
 Hospital mortality, n (%) 213 (62) 426 (66) 0.23b
Other outcomes
 Total days on ventilator, median (IQR) 6 (2–12) 4 (2–8) 0.01a
 Hypophosphatemia <2.5 mg/dl, n (%) 194 (58) 135 (22) 0.01b
 Severe hypophosphatemia <1 mg/dl, n (%) 6 (2) 79 (1) 0.37b
 Median phosphate level during CRRT, mg/dl, median (IQR) 3.7 (3.1–4.7) 4.4 (3.7–5.3) 0.01a
 Minimum phosphate level during CRRT, mg/dl, median (IQR) 2.3 (1.8–3.9) 3.4 (2.6–4.6) 0.01a
 Total phosphate replacement during CRRT, mmol, median (IQR) 62 (0–302) 0 (0–8) 0.01a
 Median ionized calcium 3.15 (1.16) 3.4 (1) 0.01c
 Positive ketones, n (%) 53 (43) 90 (40) 0.60b
 Tracheostomy, n (%) 25 (7) 19 (3) 0.01b
 Discharge disposition, n (%)
  Alive/home 196 (32) 186 (29) 0.27b
  Rehabilitation facility 19 (6) 33 (5)
  Other 5 (2) 3 (1)

Continuous data are reported as median (IQR), and categorical data are reported as counts and percentages. IQR, interquartile range; LOS, length of stay; ICU, intensive care unit; CRRT, continuous KRT.

a

Wilcoxon rank sum test.

b

Chi-squared test.

c

Independent samples t test.